APOA1 and early-onset autosomal dominant Alzheimer disease: Regarding the therapeutic importance of this study, therapies that mimic HDL function, including rHDL with apoA-I and CIGB-258, addressed to increase their stability and functionality, constitute promising treatment strategies on the three important and widespread pathologies: atherosclerosis, Alzheimer’s disease, and diabetes mellitus.